MedTrace Logo

Efficacy and Safety of OPL-0301 Compared to Placebo in Adults With Post-Myocardial Infarction (MI)

NCT05327855 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2023-02-21

No results posted yet for this study

Summary

Study OPL-0301-201 is intended to generate efficacy and safety data of OPL-0301 in participants with post-myocardial infarction (MI) left ventricular dysfunction (LVD)

Conditions

Interventions

DRUG

OPL-0301 Dose 1

Pharmaceutical form: Hard gelatin capsule; Route of administration: Oral

DRUG

OPL-0301 Dose 2

Pharmaceutical form: Hard gelatin capsule; Route of administration: Oral

DRUG

Placebo

Pharmaceutical form: Hard gelatin capsule; Route of administration: Oral

Sponsors & Collaborators

  • Valo Health, Inc.

    lead INDUSTRY

Principal Investigators

  • Victor Shi, M.D. · Valo Health, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-30
Primary Completion
2024-08-31
Completion
2024-11-30
FDA Drug
Yes

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05327855 on ClinicalTrials.gov